Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) was downgraded by research analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a report issued on Wednesday. They presently have a $42.00 target price on the stock, down from their previous target price of $63.00. Morgan Stanley’s target price would suggest a potential upside of 8.00% from the company’s current price.

Several other equities research analysts have also recently weighed in on the company. RBC Capital Markets set a $58.00 price target on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Monday. Royal Bank Of Canada decreased their price target on Teva Pharmaceutical Industries from $71.00 to $58.00 and set an “outperform” rating for the company in a research note on Monday. Barclays PLC began coverage on Teva Pharmaceutical Industries in a research note on Monday. They issued an “equal weight” rating and a $46.00 price target for the company. Bank of America Corp. cut Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and set a $48.00 price target for the company. in a research note on Monday, November 7th. Finally, HSBC cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and increased their price target for the company from $44.00 to $66.00 in a research note on Friday, November 4th. Thirteen equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $60.00.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) opened at 38.89 on Wednesday. Teva Pharmaceutical Industries has a 12-month low of $37.25 and a 12-month high of $66.55. The company has a market cap of $35.55 billion, a PE ratio of 25.98 and a beta of 0.73. The stock’s 50 day moving average price is $42.97 and its 200 day moving average price is $49.87.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.29 by $0.02. The firm earned $5.56 billion during the quarter, compared to the consensus estimate of $5.71 billion. Teva Pharmaceutical Industries had a return on equity of 16.75% and a net margin of 8.81%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same period last year, the company earned $1.35 earnings per share. Equities research analysts anticipate that Teva Pharmaceutical Industries will post $5.16 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 20th. Stockholders of record on Monday, December 5th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.50%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is presently 50.58%.

Institutional investors have recently made changes to their positions in the stock. Natixis boosted its position in shares of Teva Pharmaceutical Industries by 62.0% in the first quarter. Natixis now owns 5,197 shares of the company’s stock valued at $278,000 after buying an additional 1,988 shares during the period. Panagora Asset Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 216.5% in the first quarter. Panagora Asset Management Inc. now owns 702,480 shares of the company’s stock valued at $37,590,000 after buying an additional 480,509 shares during the period. Bridger Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at $59,320,000. Seven Eight Capital LLC boosted its position in shares of Teva Pharmaceutical Industries by 783.3% in the first quarter. Seven Eight Capital LLC now owns 31,800 shares of the company’s stock valued at $1,702,000 after buying an additional 28,200 shares during the period. Finally, Euclid Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 2.4% in the first quarter. Euclid Advisors LLC now owns 169,332 shares of the company’s stock valued at $9,061,000 after buying an additional 4,001 shares during the period. Institutional investors own 63.00% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.